Abstract
Nanomachines hold promise for the next generation of emerging technology; however, nanomachines are not a new concept. Viruses, nature’s nanomachines, have already existed for thousands of years. In 2019, the whole world had to come together to confront a life-threatening nanomachine named “SARS-CoV-2”, which causes COVID-19 illness. SARS-CoV-2, a smart nanomachine, attaches itself to the ACE2 and CD147 receptors present on the cell surfaces of the lungs, kidneys, heart, brain, intestines, testes, etc. and triggers pathogenesis. Cell entry triggers a cascade of inflammatory responses resulting in tissue damage, with the worst affected cases leading to death. SARS-CoV-2 influences several receptors and signalling pathways; therefore, finding a biomaterial that caps these signalling pathways and ligand sites is of interest. This research aimed to compare the similarities and differences between COVID-19 and its elderly sisters, MERS and SARS. Furthermore, we glanced at emerging therapeutics that carry potential in eliminating SARS-CoV-2, and the tissue damage it causes. Simple prophylactic and therapeutic strategies for the treatment of COVID- 19 infection have been put forward.
Keywords: SARS-CoV-2, COVID-19, signalling pathways, nanomachine, vaccine, drug repurposing, nanotechnology, nanomaterials.
Graphical Abstract
[1]
Drexler JF, Gloza-Rausch F, Glende J, et al. Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequences. J Virol 2010; 84(21): 11336-49.
[http://dx.doi.org/10.1128/JVI.00650-10] [PMID: 20686038]
[http://dx.doi.org/10.1128/JVI.00650-10] [PMID: 20686038]
[2]
Brooks G, Carroll K, Butel J, Morse S, Mietzner T. Chapter 11: Spore-forming gram-positive bacilli: Bacillus and Clostridium
specis In: Jawetz, melnick & Adelberg medical microbiology 2019 Abvailable from: https://accessmedicine.mhmedical.com/content.aspx?bookid=2629§ionid=217770453
[3]
Park Y-J, Walls AC, Wang Z, et al. Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors. Nat Struct Mol Biol 2019; 26(12): 1151-7.
[http://dx.doi.org/10.1038/s41594-019-0334-7] [PMID: 31792450]
[http://dx.doi.org/10.1038/s41594-019-0334-7] [PMID: 31792450]
[4]
Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270-3.
[http://dx.doi.org/10.1038/s41586-020-2012-7]
[http://dx.doi.org/10.1038/s41586-020-2012-7]
[5]
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2
cell entry depends on ACE2 and TMPRSS2 and is blocked by a
clinically proven protease inhibitor cell 2020; 181(2): 271-280e8
[6]
Jia HP, Look DC, Tan P, et al. Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. Am J Physiol Lung Cell Mol Physiol 2009; 297(1): L84-96.
[http://dx.doi.org/10.1152/ajplung.00071.2009] [PMID: 19411314]
[http://dx.doi.org/10.1152/ajplung.00071.2009] [PMID: 19411314]
[7]
Xiao F, Zimpelmann J, Burger D, Kennedy C, Hébert RL, Burns KD. Protein kinase C-δ mediates shedding of angiotensin-converting enzyme 2 from proximal tubular cells. Front Pharmacol 2016; 7: 146.
[http://dx.doi.org/10.3389/fphar.2016.00146] [PMID: 27313531]
[http://dx.doi.org/10.3389/fphar.2016.00146] [PMID: 27313531]
[8]
Kleine-Weber H, Schroeder S, Krüger N, et al. Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus. Emerg Microbes Infect 2020; 9(1): 155-68.
[http://dx.doi.org/10.1080/22221751.2020.1713705] [PMID: 31964246]
[http://dx.doi.org/10.1080/22221751.2020.1713705] [PMID: 31964246]
[9]
Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology 2018; 23(2): 130-7.
[http://dx.doi.org/10.1111/resp.13196] [PMID: 29052924]
[http://dx.doi.org/10.1111/resp.13196] [PMID: 29052924]
[10]
Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020; 11(1): 222.
[http://dx.doi.org/10.1038/s41467-019-13940-6] [PMID: 31924756]
[http://dx.doi.org/10.1038/s41467-019-13940-6] [PMID: 31924756]
[11]
Breban R, Riou J, Fontanet A. Interhuman transmissibility of Middle East respiratory syndrome coronavirus: Estimation of pandemic risk. Lancet 2013; 382(9893): 694-9.
[http://dx.doi.org/10.1016/S0140-6736(13)61492-0] [PMID: 23831141]
[http://dx.doi.org/10.1016/S0140-6736(13)61492-0] [PMID: 23831141]
[12]
Chowell G, Castillo-Chavez C, Fenimore PW, Kribs-Zaleta CM, Arriola L, Hyman JM. Model parameters and outbreak control for SARS. Emerg Infect Dis 2004; 10(7): 1258-63.
[http://dx.doi.org/10.3201/eid1007.030647] [PMID: 15324546]
[http://dx.doi.org/10.3201/eid1007.030647] [PMID: 15324546]
[13]
Kang CK, Song K-H, Choe PG, et al. Clinical and epidemiologic characteristics of spreaders of Middle East respiratory syndrome coronavirus during the 2015 outbreak in Korea. J Korean Med Sci 2017; 32(5): 744-9.
[http://dx.doi.org/10.3346/jkms.2017.32.5.744] [PMID: 28378546]
[http://dx.doi.org/10.3346/jkms.2017.32.5.744] [PMID: 28378546]
[14]
Grijalva CG, Rolfes MA, Zhu Y, et al. Transmission of SARS-COV-2 infections in households-Tennessee and Wisconsin, April-September 2020. MMWR Morb Mortal Wkly Rep 2020; 69(44): 1631-4.
[http://dx.doi.org/10.15585/mmwr.mm6944e1] [PMID: 33151916]
[http://dx.doi.org/10.15585/mmwr.mm6944e1] [PMID: 33151916]
[15]
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020; 395(10223): 507-13.
[http://dx.doi.org/10.1016/S0140-6736(20)30211-7] [PMID: 32007143]
[http://dx.doi.org/10.1016/S0140-6736(20)30211-7] [PMID: 32007143]
[16]
Sahin AR, Erdogan A, Agaoglu PM, et al. 2019 novel coronavirus (COVID-19) outbreak: A review of the current literature. EJMO 2020; 4(1): 1-7.
[http://dx.doi.org/10.14744/ejmo.2020.12220]
[http://dx.doi.org/10.14744/ejmo.2020.12220]
[17]
Symptoms, spread and other essential information about
coronavirus and COVID-19 Harvard Health Publishing 2021
Abvailable from: https://www.health.harvard.edu/diseases-and-conditions/covid-19-basics
[18]
Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19: An overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr Infect Dis J 2020; 39(5): 355-68.
[http://dx.doi.org/10.1097/INF.0000000000002660] [PMID: 32310621]
[http://dx.doi.org/10.1097/INF.0000000000002660] [PMID: 32310621]
[19]
Alhogbani T. Acute myocarditis associated with novel Middle East respiratory syndrome coronavirus. Ann Saudi Med 2016; 36(1): 78-80.
[http://dx.doi.org/10.5144/0256-4947.2016.78] [PMID: 26922692]
[http://dx.doi.org/10.5144/0256-4947.2016.78] [PMID: 26922692]
[20]
Fan C, Li K, Ding Y, Lu WL, Wang J. ACE2 expression in kidney and testis may cause kidney and testis infection in COVID-19 patients. Front Med 2021; 7: 1045.
[21]
Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: Tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci 2020; 11(7): 995-8.
[http://dx.doi.org/10.1021/acschemneuro.0c00122] [PMID: 32167747]
[http://dx.doi.org/10.1021/acschemneuro.0c00122] [PMID: 32167747]
[22]
Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020; 92(6): 552-5.
[http://dx.doi.org/10.1002/jmv.25728] [PMID: 32104915]
[http://dx.doi.org/10.1002/jmv.25728] [PMID: 32104915]
[23]
de Wilde AH, Raj VS, Oudshoorn D, et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment. J Gen Virol 2013; 94(Pt 8): 1749-60.
[http://dx.doi.org/10.1099/vir.0.052910-0] [PMID: 23620378]
[http://dx.doi.org/10.1099/vir.0.052910-0] [PMID: 23620378]
[24]
Jin W, Dong C. IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect 2013; 2(9)e60
[PMID: 26038490]
[PMID: 26038490]
[25]
Mubarak A, Alturaiki W, Hemida MG. Middle East respiratory syndrome coronavirus (MERS-CoV): Infection, immunological response, and vaccine development. J Immunol Res 2019; 20196491738
[http://dx.doi.org/10.1155/2019/6491738] [PMID: 31089478]
[http://dx.doi.org/10.1155/2019/6491738] [PMID: 31089478]
[26]
Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): A systematic review and meta-analysis. Int J Infect Dis 2016; 49: 129-33.
[http://dx.doi.org/10.1016/j.ijid.2016.06.015] [PMID: 27352628]
[http://dx.doi.org/10.1016/j.ijid.2016.06.015] [PMID: 27352628]
[27]
WHO. Clinical management of severe acute respiratory infection
(SARI) when COVID-19 disease is suspected. 2020. Available
from: . https://apps.who.int/iris/handle/10665/331446
[28]
Tikellis C, Thomas MC. Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. Int J Pept 2012; 2012256294
[http://dx.doi.org/10.1155/2012/256294] [PMID: 22536270]
[http://dx.doi.org/10.1155/2012/256294] [PMID: 22536270]
[29]
Jando J, Camargo SMR, Herzog B, Verrey F. Expression and regulation of the neutral amino acid transporter B0AT1 in rat small intestine. PLoS One 2017; 12(9)e0184845
[http://dx.doi.org/10.1371/journal.pone.0184845] [PMID: 28915252]
[http://dx.doi.org/10.1371/journal.pone.0184845] [PMID: 28915252]
[30]
Kuba K, Zhang L, Imai Y, et al. Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload. Circ Res 2007; 101(4): e32-42.
[http://dx.doi.org/10.1161/CIRCRESAHA.107.158659] [PMID: 17673668]
[http://dx.doi.org/10.1161/CIRCRESAHA.107.158659] [PMID: 17673668]
[31]
Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020; 17(5): 259-60.
[http://dx.doi.org/10.1038/s41569-020-0360-5] [PMID: 32139904]
[http://dx.doi.org/10.1038/s41569-020-0360-5] [PMID: 32139904]
[32]
Menachery VD, Yount BL Jr, Debbink K, et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med 2015; 21(12): 1508-13.
[http://dx.doi.org/10.1038/nm.3985] [PMID: 26552008]
[http://dx.doi.org/10.1038/nm.3985] [PMID: 26552008]
[33]
Ulrich H, Pillat MM. CD147 as a target for COVID-19 treatment:
Suggested effects of azithromycin and stem cell engagement. Stem
cell reviews and reports 2020; 16(3): 434-40..
[34]
Cascella M, Rajnik M, Aleem A, et al. Features, evaluation, and
treatment of coronavirus (COVID-19) [Updated 2021 Apr 20]. In:
StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing;
2021. Available from: . https://www.ncbi.nlm.nih.gov/books/NBK554776.
[35]
Sun J, He W-T, Wang L, et al. COVID-19: Epidemiology, evolution, and cross-disciplinary perspectives. Trends Mol Med 2020; 26(5): 483-95.
[http://dx.doi.org/10.1016/j.molmed.2020.02.008] [PMID: 32359479]
[http://dx.doi.org/10.1016/j.molmed.2020.02.008] [PMID: 32359479]
[36]
Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020; 367(6483): 1260-3.
[http://dx.doi.org/10.1126/science.abb2507] [PMID: 32075877]
[http://dx.doi.org/10.1126/science.abb2507] [PMID: 32075877]
[37]
Swerdlow DL, Finelli L. Preparation for possible sustained transmission of 2019 novel coronavirus: Lessons from previous epidemics. JAMA 2020; 323(12): 1129-30.
[http://dx.doi.org/10.1001/jama.2020.1960] [PMID: 32207807]
[http://dx.doi.org/10.1001/jama.2020.1960] [PMID: 32207807]
[38]
Woo P, Yuen K, Lau S. Epidemiology of coronavirus-associated respiratory tract infections and the role of rapid diagnostic tests: A prospective study. Hong Kong Med J 2012; 18: 22-4.
[39]
Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382(10): 929-36.
[http://dx.doi.org/10.1056/NEJMoa2001191] [PMID: 32004427]
[http://dx.doi.org/10.1056/NEJMoa2001191] [PMID: 32004427]
[40]
Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020; 323(18): 1843-4.
[http://dx.doi.org/10.1001/jama.2020.3786] [PMID: 32159775]
[http://dx.doi.org/10.1001/jama.2020.3786] [PMID: 32159775]
[41]
Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: A preliminary study. JAMA 2003; 290(24): 3222-8.
[http://dx.doi.org/10.1001/jama.290.24.3222] [PMID: 14693875]
[http://dx.doi.org/10.1001/jama.290.24.3222] [PMID: 14693875]
[42]
Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361(9366): 1319-25.
[http://dx.doi.org/10.1016/S0140-6736(03)13077-2] [PMID: 12711465]
[http://dx.doi.org/10.1016/S0140-6736(03)13077-2] [PMID: 12711465]
[43]
Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis. J Infect Dis 2015; 211(1): 80-90.
[http://dx.doi.org/10.1093/infdis/jiu396] [PMID: 25030060]
[http://dx.doi.org/10.1093/infdis/jiu396] [PMID: 25030060]
[44]
WHO. Clinical management of severe acute respiratory infection
when Middle East respiratory syndrome coronavirus (MERSCoV)
infection is suspected. Interim guidance 2019. Available
from:. https://apps.who.int/iris/handle/10665/178529
[45]
Stockman LJ, Bellamy R, Garner P. SARS: Systematic review of treatment effects. PLoS Med 2006; 3(9)e343
[http://dx.doi.org/10.1371/journal.pmed.0030343] [PMID: 16968120]
[http://dx.doi.org/10.1371/journal.pmed.0030343] [PMID: 16968120]
[46]
Spanakis N, Tsiodras S, Haagmans BL, et al. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents 2014; 44(6): 528-32.
[http://dx.doi.org/10.1016/j.ijantimicag.2014.07.026] [PMID: 25288266]
[http://dx.doi.org/10.1016/j.ijantimicag.2014.07.026] [PMID: 25288266]
[47]
Zhao G, He L, Sun S, et al. A novel nanobody targeting Middle East respiratory syndrome coronavirus (MERS-CoV) receptor-binding domain has potent cross-neutralizing activity and protective efficacy against MERS-CoV. J Virol 2018; 92(18): e00837-18.
[http://dx.doi.org/10.1128/JVI.00837-18] [PMID: 29950421]
[http://dx.doi.org/10.1128/JVI.00837-18] [PMID: 29950421]
[48]
Tavakol S, Alavijeh MS, Seifalian AM. Covid-19 vaccines in clinical trials and their mode of action for immunity against the virus. Curr Pharm Des 2021; 27(13): 1553-63.
[http://dx.doi.org/10.2174/1381612826666201023143956] [PMID: 33100195]
[http://dx.doi.org/10.2174/1381612826666201023143956] [PMID: 33100195]
[49]
Zumla A, Chan JF, Azhar EI, Hui DS, Yuen K-Y. Coronaviruses-drug discovery and therapeutic options. Nat Rev Drug Discov 2016; 15(5): 327-47.
[http://dx.doi.org/10.1038/nrd.2015.37] [PMID: 26868298]
[http://dx.doi.org/10.1038/nrd.2015.37] [PMID: 26868298]
[50]
Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike
glycoprotein cell 2020; 181(2): 281-292e6
[51]
Gadalla MR, Veit M. Toward the identification of ZDHHC enzymes required for palmitoylation of viral protein as potential drug targets. Expert Opin Drug Discov 2020; 15(2): 159-77.
[http://dx.doi.org/10.1080/17460441.2020.1696306] [PMID: 31809605]
[http://dx.doi.org/10.1080/17460441.2020.1696306] [PMID: 31809605]
[52]
Lowe D. Covid-19 small molecule therapies reviewed Sci Transl
Med 2020 Available from: https://blogs.sciencemag.org/pipeline/archives/2020/03/06/covid-19-small-molecule-therapies-reviewed
[53]
Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020; 19(3): 149-50.
[http://dx.doi.org/10.1038/d41573-020-00016-0] [PMID: 32127666]
[http://dx.doi.org/10.1038/d41573-020-00016-0] [PMID: 32127666]
[54]
Tim Smith, Prosser T. COVID-19 drug therapy-potential options.
Clinical drug information, clinical solutions 2020. Abvailable from:. https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options. html
[55]
Guo J, Guo W, Jin X, Liu Y, Zhang L, Zhang J. Effects of angiotensin II type 1 receptor antagonist on rats with septic shock. Int J Clin Exp Med 2015; 8(5): 7867-71.
[PMID: 26221342]
[PMID: 26221342]
[56]
Janssen . Janssen. Johnson & johnson announces collaboration with
U.S. department of health & human services to accelerate
development of a potential novel coronavirus vaccine. 2020.
Available from:. http://www.janssen.com/johnson-johnson-announces-collaboration-us-department-health-human-services-accelerate-development
[57]
Novavax Novavax awarded funding from cepi for COVID-19
vaccine development 2020 Available from: https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine development#:~:text=(NASDAQ%3A% 20NVAX)%2C%20a,develop%20a%20COVID%2D19%20vaccine.
[58]
Tavakol S, Seifalian AM. Vitamin E at a high dose as an anti-ferroptosis drug and not just a supplement for COVID-19 treatment. Biotechnol Appl Biochem 2021; 1: 1-3.
[http://dx.doi.org/10.1002/bab.2176] [PMID: 33938041]
[http://dx.doi.org/10.1002/bab.2176] [PMID: 33938041]
[59]
Zhou T-B, Wu W-F, Qin Y-H, Yin S-S. Association of all-trans retinoic acid treatment with the renin-angiotensin aldosterone system expression in glomerulosclerosis rats. J Renin Angiotensin Aldosterone Syst 2013; 14(4): 299-307.
[http://dx.doi.org/10.1177/1470320312465220] [PMID: 23144044]
[http://dx.doi.org/10.1177/1470320312465220] [PMID: 23144044]
[60]
Martineau AR, Jolliffe DA, Greenberg L, et al. Vitamin D supplementation to prevent acute respiratory infections: Individual participant data meta-analysis. Health Technol Assess 2019; 23(2): 1-44.
[http://dx.doi.org/10.3310/hta23020] [PMID: 30675873]
[http://dx.doi.org/10.3310/hta23020] [PMID: 30675873]
[61]
Hewison M. Antibacterial effects of vitamin D. Nat Rev Endocrinol 2011; 7(6): 337-45.
[http://dx.doi.org/10.1038/nrendo.2010.226] [PMID: 21263449]
[http://dx.doi.org/10.1038/nrendo.2010.226] [PMID: 21263449]
[62]
Xystrakis E, Kusumakar S, Boswell S, et al. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest 2006; 116(1): 146-55.
[http://dx.doi.org/10.1172/JCI21759] [PMID: 16341266]
[http://dx.doi.org/10.1172/JCI21759] [PMID: 16341266]
[63]
Pilz S, Verheyen N, Grübler MR, Tomaschitz A, März W. Vitamin D and cardiovascular disease prevention. Nat Rev Cardiol 2016; 13(7): 404-17.
[http://dx.doi.org/10.1038/nrcardio.2016.73] [PMID: 27150190]
[http://dx.doi.org/10.1038/nrcardio.2016.73] [PMID: 27150190]
[64]
Rogovskii VS. The linkage between inflammation and immune tolerance: Interfering with inflammation in cancer. Curr Cancer Drug Targets 2017; 17(4): 325-32.
[http://dx.doi.org/10.2174/1568009617666170109110816] [PMID: 28067176]
[http://dx.doi.org/10.2174/1568009617666170109110816] [PMID: 28067176]
[65]
Carr AC, Maggini S. Vitamin C and immune function. Nutrients 2017; 9(11): 1211.
[http://dx.doi.org/10.3390/nu9111211] [PMID: 29099763]
[http://dx.doi.org/10.3390/nu9111211] [PMID: 29099763]
[66]
Tavakol S, Zahmatkeshan M, Mohammadinejad R, et al. The role of nanotechnology in current COVID-19 outbreak. Heliyon 2021; 7(4)e06841
[http://dx.doi.org/10.1016/j.heliyon.2021.e06841] [PMID: 33880422]
[http://dx.doi.org/10.1016/j.heliyon.2021.e06841] [PMID: 33880422]
[67]
Tavakol S, Hoveizi E, Kharrazi S, Tavakol B, Karimi S, Rezayat Sorkhabadi SM. Organelles and chromatin fragmentation of human umbilical vein endothelial cell influence by the effects of zeta potential and size of silver nanoparticles in different manners. Artif Cells Nanomed Biotechnol 2017; 45(4): 817-23.
[http://dx.doi.org/10.1080/21691401.2016.1178132] [PMID: 27160016]
[http://dx.doi.org/10.1080/21691401.2016.1178132] [PMID: 27160016]
[68]
Das C, Paul SS, Saha A, et al. Silver-based nanomaterials as therapeutic agents against coronaviruses: A review. Int J Nanomedicine 2020; 15: 9301-15.
[http://dx.doi.org/10.2147/IJN.S280976] [PMID: 33262589]
[http://dx.doi.org/10.2147/IJN.S280976] [PMID: 33262589]
[69]
Saburi E, Abazari MF, Hassannia H, et al. The use of mesenchymal stem cells in the process of treatment and tissue regeneration after recovery in patients with Covid-19. Gene 2021; 777145471
[70]
Rodini CO, Gonçalves da Silva PB, Assoni AF, Carvalho VM, Okamoto OK. Mesenchymal stem cells enhance tumorigenic properties of human glioblastoma through independent cell-cell communication mechanisms. Oncotarget 2018; 9(37): 24766-77.
[http://dx.doi.org/10.18632/oncotarget.25346] [PMID: 29872504]
[http://dx.doi.org/10.18632/oncotarget.25346] [PMID: 29872504]
[71]
Basiri A, Mansouri F, Azari A, et al. Stem cell therapy potency in personalizing severe COVID-19 treatment. Stem Cell Rev Rep 2021; 17(1): 193-213.
[72]
Market M, Angka L, Martel AB, et al. Flattening the COVID-19 curve with natural killer cell based immunotherapies. Front Immunol 2020; 11: 1512.
[http://dx.doi.org/10.3389/fimmu.2020.01512] [PMID: 32655581]
[http://dx.doi.org/10.3389/fimmu.2020.01512] [PMID: 32655581]
[73]
Bank AD. Covid-19 outbreak to have significant economic impact
on developing asia 2020 Available from: https://www.adb.org/news/covid-19-outbreak-have-significant-economic-impact-developing-asia#:~:text=MANILA%2C%20PHILIPPINES%20
[74]
Wang K, Chen W, Zhou Y-S, et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. Signal Transduct Target Ther 2020; 5(1): 283.
[http://dx.doi.org/10.1101/2020.03.14.988345]
[http://dx.doi.org/10.1101/2020.03.14.988345]
[75]
Tavakol S, Ashrafizadeh M, Deng S, et al. Autophagy modulators: Mechanistic aspects and drug delivery systems. Biomolecules 2019; 9(10): 530.
[http://dx.doi.org/10.3390/biom9100530] [PMID: 31557936]
[http://dx.doi.org/10.3390/biom9100530] [PMID: 31557936]
Article Metrics
17
3